Data to be Presented at AACR Annual Meeting 2026

Summary by AI BETAClose X

HUTCHMED announced that new and updated data from several studies will be presented at the AACR Annual Meeting 2026, including preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate, which demonstrated potent inhibition of PI3K and PIKK family kinases with IC50s around 1 to 10 nM and robust anti-tumor effects in preclinical models. Updated results from a Phase Ib/II trial of surufatinib plus sintilimab and capecitabine in metastatic small bowel adenocarcinoma and appendiceal carcinoma, and an exploratory Phase II study of surufatinib combined with gemcitabine and nab-paclitaxel for pancreatic ductal adenocarcinoma will also be presented.

Disclaimer*

UK 100

Latest directors dealings